Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT04976738
Registration number
NCT04976738
Ethics application status
Date submitted
30/06/2021
Date registered
26/07/2021
Date last updated
7/07/2022
Titles & IDs
Public title
A Study of Cybis™ 10:25 THC:CBD Oil in Adults With Chronic Back/Neck Pain
Query!
Scientific title
A Dose-ranging Study to Examine the Pharmacokinetics, Safety, Tolerability and Efficacy of Cybis™ 10:25 THC:CBD Oil in Adults With Chronic Back/Neck Pain
Query!
Secondary ID [1]
0
0
CYM-001-21
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
CYDEPS
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Chronic Pain
0
0
Query!
Neck Pain
0
0
Query!
Back Pain
0
0
Query!
Pain
0
0
Query!
Pain, Chronic
0
0
Query!
Pain, Back
0
0
Query!
Pain, Neck
0
0
Query!
CBD
0
0
Query!
THC
0
0
Query!
Condition category
Condition code
Musculoskeletal
0
0
0
0
Query!
Other muscular and skeletal disorders
Query!
Neurological
0
0
0
0
Query!
Other neurological disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Cybis™ 10:25 THC:CBD oil
Experimental: Treatment arm: Cybis™ 10:25 THC:CBD oil - Cybis™ 10:25 THC:CBD oil administered oromucosally at doses varying from 0.5 mL once daily to 1.5 mL twice daily. Total duration of dosing is 28 days.
Treatment: Drugs: Cybis™ 10:25 THC:CBD oil
Cybis™ 10:25 containing 10 mg/mL of D9-THC and 25 mg/mL of CBD, formulated in medium chain triglycerides (MCT)
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number (and percentage) of participants with one or more adverse event
Query!
Assessment method [1]
0
0
To assess the safety and tolerability of Cybis™ 10:25 at low (0.5 mL qd), medium-low (0.5 mL bd), medium (1.0 mL bd) and high (1.5 mL bd) doses.
Query!
Timepoint [1]
0
0
Safety and tolerability will be assessed throughout the trial. Up to 35 days.
Query!
Primary outcome [2]
0
0
Number (and percentage) of participants with one or more adverse event of special interest
Query!
Assessment method [2]
0
0
To assess the safety and tolerability of Cybis™ 10:25 at low (0.5 mL qd), medium-low (0.5 mL bd), medium (1.0 mL bd) and high (1.5 mL bd) doses.
Query!
Timepoint [2]
0
0
Safety and tolerability will be assessed throughout the trial. Up to 35 days.
Query!
Primary outcome [3]
0
0
Number (and percentage) of participants with one or more serious adverse events
Query!
Assessment method [3]
0
0
To assess the safety and tolerability of Cybis™ 10:25 at low (0.5 mL qd), medium-low (0.5 mL bd), medium (1.0 mL bd) and high (1.5 mL bd) doses.
Query!
Timepoint [3]
0
0
Safety and tolerability will be assessed throughout the trial. Up to 35 days.
Query!
Primary outcome [4]
0
0
Adverse events, adverse events of special interest, serious adverse events will be summarised descriptively with the number of participants experiencing the event and the percentages of participants experiencing the event.
Query!
Assessment method [4]
0
0
To assess the safety and tolerability of Cybis™ 10:25 at low (0.5 mL qd), medium-low (0.5 mL bd), medium (1.0 mL bd) and high (1.5 mL bd) doses.
Query!
Timepoint [4]
0
0
Safety and tolerability will be assessed throughout the trial. Up to 35 days.
Query!
Primary outcome [5]
0
0
Number (and percentage) of participants with changes in vital signs
Query!
Assessment method [5]
0
0
To assess the safety and tolerability of Cybis™ 10:25 at low (0.5 mL qd), medium-low (0.5 mL bd), medium (1.0 mL bd) and high (1.5 mL bd) doses.
Query!
Timepoint [5]
0
0
Safety and tolerability will be assessed throughout the trial. Up to 35 days.
Query!
Primary outcome [6]
0
0
Number (and percentage) of participants with clinically relevant changes in physical examination
Query!
Assessment method [6]
0
0
To assess the safety and tolerability of Cybis™ 10:25 at low (0.5 mL qd), medium-low (0.5 mL bd), medium (1.0 mL bd) and high (1.5 mL bd) doses.
Query!
Timepoint [6]
0
0
Safety and tolerability will be assessed throughout the trial. Up to 35 days.
Query!
Primary outcome [7]
0
0
Number (and percentage) of participants with clinically relevant changes in clinical chemistry
Query!
Assessment method [7]
0
0
To assess the safety and tolerability of Cybis™ 10:25 at low (0.5 mL qd), medium-low (0.5 mL bd), medium (1.0 mL bd) and high (1.5 mL bd) doses.
Query!
Timepoint [7]
0
0
Safety and tolerability will be assessed throughout the trial. Up to 35 days.
Query!
Primary outcome [8]
0
0
Number (and percentage) of participants who drop-out
Query!
Assessment method [8]
0
0
To assess the safety and tolerability of Cybis™ 10:25 at low (0.5 mL qd), medium-low (0.5 mL bd), medium (1.0 mL bd) and high (1.5 mL bd) doses.
Query!
Timepoint [8]
0
0
Safety and tolerability will be assessed throughout the trial. Up to 35 days.
Query!
Primary outcome [9]
0
0
Number (and percentage) of participants who withdraw due to adverse events
Query!
Assessment method [9]
0
0
To assess the safety and tolerability of Cybis™ 10:25 at low (0.5 mL qd), medium-low (0.5 mL bd), medium (1.0 mL bd) and high (1.5 mL bd) doses.
Query!
Timepoint [9]
0
0
Safety and tolerability will be assessed throughout the trial. Up to 35 days.
Query!
Secondary outcome [1]
0
0
To investigate the pharmacokinetics of Cybis™ 10:25 in participants with chronic back and neck pain following single and repeated doses. Peak plasma concentration (Cmax) of THC in plasma.
Query!
Assessment method [1]
0
0
To investigate the pharmacokinetics of Cybis™ 10:25 in participants with chronic back and neck pain following single and repeated doses. The concentration at peak (Cmax) will be calculated for THC. Pharmacokinetic calculations will be conducted for each dose level individually.
Query!
Timepoint [1]
0
0
Up to 29 days. Samples collected at baseline 0 (pre-dose), 0.25, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 9.0, 12.0, and 24.0 hours post dosing. Day 8, 15, 22 and 29 trough levels.
Query!
Secondary outcome [2]
0
0
To investigate the pharmacokinetics of Cybis™ 10:25 in participants with chronic back and neck pain following single and repeated doses. Time to maximum concentration (tmax) of THC in plasma.
Query!
Assessment method [2]
0
0
To investigate the pharmacokinetics of Cybis™ 10:25 in participants with chronic back and neck pain following single and repeated doses. The time to reach peak (tmax) will be calculated for THC. Pharmacokinetic calculations will be conducted for each dose level individually.
Query!
Timepoint [2]
0
0
Up to 29 days. Samples collected at baseline 0 (pre-dose), 0.25, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 9.0, 12.0, and 24.0 hours post dosing. Day 8, 15, 22 and 29 trough levels.
Query!
Secondary outcome [3]
0
0
To investigate the pharmacokinetics of Cybis™ 10:25 in participants with chronic back and neck pain following single and repeated doses. Area under the concentration/time curve (AUC) will be calculated for THC.
Query!
Assessment method [3]
0
0
To investigate the pharmacokinetics of Cybis™ 10:25 in participants with chronic back and neck pain following single and repeated doses. The area under the concentration/time curve (AUC) will be calculated for THC. Pharmacokinetic calculations will be conducted for each dose level individually.
Query!
Timepoint [3]
0
0
Up to 29 days. Samples collected at baseline 0 (pre-dose), 0.25, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 9.0, 12.0, and 24.0 hours post dosing. Day 8, 15, 22 and 29 trough levels.
Query!
Secondary outcome [4]
0
0
To investigate the pharmacokinetics of Cybis™ 10:25 in participants with chronic back and neck pain following single and repeated doses. The elimination half-life (t1/2) will be calculated for THC.
Query!
Assessment method [4]
0
0
To investigate the pharmacokinetics of Cybis™ 10:25 in participants with chronic back and neck pain following single and repeated doses. The elimination half-life (t1/2) will be calculated for THC. Pharmacokinetic calculations will be conducted for each dose level individually.
Query!
Timepoint [4]
0
0
Up to 29 days. Samples collected at baseline 0 (pre-dose), 0.25, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 9.0, 12.0, and 24.0 hours post dosing. Day 8, 15, 22 and 29 trough levels.
Query!
Secondary outcome [5]
0
0
To investigate the pharmacokinetics of Cybis™ 10:25 in participants with chronic back and neck pain following single and repeated doses. Peak plasma concentration (Cmax) of CBD in plasma.
Query!
Assessment method [5]
0
0
To investigate the pharmacokinetics of Cybis™ 10:25 in participants with chronic back and neck pain following single and repeated doses. The concentration at peak (Cmax) will be calculated for CBD. Pharmacokinetic calculations will be conducted for each dose level individually.
Query!
Timepoint [5]
0
0
Up to 29 days. Samples collected at baseline 0 (pre-dose), 0.25, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 9.0, 12.0, and 24.0 hours post dosing. Day 8, 15, 22 and 29 trough levels.
Query!
Secondary outcome [6]
0
0
To investigate the pharmacokinetics of Cybis™ 10:25 in participants with chronic back and neck pain following single and repeated doses. Time to maximum concentration (tmax) of CBD in plasma.
Query!
Assessment method [6]
0
0
To investigate the pharmacokinetics of Cybis™ 10:25 in participants with chronic back and neck pain following single and repeated doses. The Time to maximum concentration (tmax) will be calculated for CBD. Pharmacokinetic calculations will be conducted for each dose level individually.
Query!
Timepoint [6]
0
0
Up to 29 days. Samples collected at baseline 0 (pre-dose), 0.25, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 9.0, 12.0, and 24.0 hours post dosing. Day 8, 15, 22 and 29 trough levels.
Query!
Secondary outcome [7]
0
0
To investigate the pharmacokinetics of Cybis™ 10:25 in participants with chronic back and neck pain following single and repeated doses. The area under the concentration/time curve (AUC) will be calculated for CBD.
Query!
Assessment method [7]
0
0
To investigate the pharmacokinetics of Cybis™ 10:25 in participants with chronic back and neck pain following single and repeated doses. The area under the concentration/time curve (AUC) will be calculated for CBD. Pharmacokinetic calculations will be conducted for each dose level individually.
Query!
Timepoint [7]
0
0
Up to 29 days. Samples collected at baseline 0 (pre-dose), 0.25, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 9.0, 12.0, and 24.0 hours post dosing. Day 8, 15, 22 and 29 trough levels.
Query!
Secondary outcome [8]
0
0
To investigate the pharmacokinetics of Cybis™ 10:25 in participants with chronic back and neck pain following single and repeated doses. The elimination half-life (t1/2) will be calculated for CBD.
Query!
Assessment method [8]
0
0
To investigate the pharmacokinetics of Cybis™ 10:25 in participants with chronic back and neck pain following single and repeated doses. The elimination half-life (t1/2) will be calculated for CBD. Pharmacokinetic calculations will be conducted for each dose level individually.
Query!
Timepoint [8]
0
0
Up to 29 days. Samples collected at baseline 0 (pre-dose), 0.25, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 9.0, 12.0, and 24.0 hours post dosing. Day 8, 15, 22 and 29 trough levels.
Query!
Secondary outcome [9]
0
0
To investigate the dose-response relationship between Cybis™ 10:25 and pain response, as measured by the change from baseline in Numerical Pain Rating Scale (NPRS)
Query!
Assessment method [9]
0
0
To investigate the dose-response relationship between Cybis™ 10:25 and pain response as measured by the change from baseline in Numerical Pain Rating Scale (NPRS).
The NPRS is an 11-point scale between 0 (no pain) and 10 (worst pain ever possible). The minimum clinically significant change in NPRS is two points. The NPRS has been validated for use in participant with low back pain.
Baseline pain levels are considered the NPRS at Day 1, irrespective of dose cohort. Change from baseline will be calculated as the pain level at the end of a dose cohort (Day 8 for 0.5 mL once daily; Day 15 for 0.5 mL bd; Day 22 for 1.0 mL bd; or Day 29 for 1.5 mL bd) minus the Day 1 value.
Query!
Timepoint [9]
0
0
Baseline (pre-dose), Day 1, 8, 15, 22, 29 and 35
Query!
Secondary outcome [10]
0
0
To investigate the dose-response relationship between Cybis™ 10:25 and pain response, as measured by the change from baseline in Brief Pain Inventory - Short Form.
Query!
Assessment method [10]
0
0
To investigate the dose-response relationship between Cybis™ 10:25 and pain response as measured by the change from baseline in Brief Pain Inventory - Short Form.
The Brief Pain Inventory-Short Form is a questionnaire that assesses worst pain in the last 24 hours, least pain in the last 24 hours, average pain, and pain 'right now' along with the interference the pain causes on general activity, mood, walking ability, normal work, relations with others, sleep and enjoyment of life. It will be scored according to its scoring manual [24]. Scores will be summarised at baseline, Day 8, 15, 22, 29 and 35.
Query!
Timepoint [10]
0
0
Baseline (pre-dose), Day 1, 8, 15, 22, 29 and 35
Query!
Secondary outcome [11]
0
0
To investigate the dose-response relationship between Cybis™ 10:25 and quality of life as measured by the change from baseline in Depression Anxiety Stress Scale.
Query!
Assessment method [11]
0
0
To investigate the dose-response relationship between Cybis™ 10:25 and quality of life as measured by the change from baseline in Depression Anxiety Stress Scale.
The Depression Anxiety Stress Scale (DASS) is a 21-item self-report instrument used to measure depression, anxiety and stress. The DASS will be scored according to its scoring manual. Participants will be categorised as having normal, mild, moderate, severe, or extremely severe symptoms. Lower scores indicate normal symptoms, whereas higher scores indicate severe symptoms.
Changes from baseline in DASS subscale scores will be used to investigate the dose-response relationship.
Query!
Timepoint [11]
0
0
Baseline (pre-dose), Day 1, 8, 15, 22, 29 and 35
Query!
Secondary outcome [12]
0
0
To investigate the dose-response relationship between Cybis™ 10:25 and quality of life as measured by the change from baseline in Medical Outcomes Sleep Survey.
Query!
Assessment method [12]
0
0
To investigate the dose-response relationship between Cybis™ 10:25 and quality of life as measured by the change from baseline in Medical Outcomes Sleep Survey.
The Medical Outcomes Sleep Scale is a 12-item scale that assesses sleep disturbance, sleep adequacy, somnolence, quantity of sleep, snoring, and awakening short of breath or with a headache. It will be scored according to its scoring manual.
The change in MOS Sleep Problems Index will be used to investigate the dose-response relationship.
Query!
Timepoint [12]
0
0
Baseline (pre-dose), Day 1, 8, 15, 22, 29 and 35
Query!
Secondary outcome [13]
0
0
To investigate the dose-response relationship between Cybis™ 10:25 and quality of life as measured by the change from baseline in Self-Assessment of Treatment (SAT-II) scale.
Query!
Assessment method [13]
0
0
To investigate the dose-response relationship between Cybis™ 10:25 and quality of life as measured by the change from baseline in in Self-Assessment of Treatment (SAT-II) scale.
The Self-Assessment of Treatment is a 9-item scale that measures treatment satisfaction in the previous seven days. It assesses pain, self-care activities, daily activities, physical activities, emotional well-being, sleep and social functioning, all assessed on a 5-point Likert scale. It also captures how likely the respondent would be willing to receive the study treatment again, and how study treatment compares to other treatments. The SAT-II has been validated, and is considered an acceptable endpoint for pain studies. The change in Self-Assessment of Treatment score will be used to investigate the dose-response relationship.
Query!
Timepoint [13]
0
0
Baseline (pre-dose), Day 1, 8, 15, 22, 29 and 35
Query!
Secondary outcome [14]
0
0
To investigate rescue medication use in participants prescribed Cybis™ 10:25 (proportion of patients requiring rescue medication, the number of doses of rescue medication required, the time to rescue medication).
Query!
Assessment method [14]
0
0
To investigate rescue medication use in participants prescribed Cybis™ 10:25 for chronic back and neck pain.
The proportion of patients requiring rescue medication and the number of doses of rescue medication required will be analysed descriptively. The time to first dose of rescue medication will be calculated using Kaplan-Meier methods.
Query!
Timepoint [14]
0
0
Day 1, 8, 15, 22, 29 and 35
Query!
Eligibility
Key inclusion criteria
1. Aged over 18 years and less than 75 years of age on the date of the Screening Visit;
2. Have back and or neck pain of at least three months duration;
3. Have an average back or neck pain score of between 5 and 9 on a 10-point visual
analogue pain scale;
4. Have failed to achieve self-reported satisfactory pain relief using over-the-counter
paracetamol or non-steroidal anti-inflammatory drugs (NSAIDs);
5. Are willing to cease all current pain medications 14 days prior to commencing Cybis™
10:25, and for the duration of the study (except as allowed under rescue medication);
Note: Pain medication may include opioids (including but not limited to
paracetamol+codeine combinations, codeine, tramadol, tapentadol, buprenorphine),
NSAIDs and other co-analgesic medications (such as anti-epileptics, antidepressants,
clonidine) and/or any other pain medications.
6. Agree to cease any dietary or herbal supplements (e.g. St John's Wort) fourteen days
prior to commencing Cybis™ 10:25, and for the duration of the study;
7. Are willing to cease driving a car or operating heavy machinery from the day of first
dosing to seven days after administration of the last dose of Cybis™ 10:25;
8. Agree to use contraception throughout the study, and for one month after the last dose
of Cybis™ 10:25 is administered (if reproductive age female) or three months after the
last dose of Cybis™ 10:25 is administered (if male); Note: women of childbearing
potential must have a negative serum or urine pregnancy test prior to entry into the
study. For women, adequate contraception is a double barrier method for the duration
of the study and for 30 days post the last study dose. For men, barrier contraception
is required for the duration of the study and for 3 months after the last study dose.
9. Agree to adhere to the study protocol; and
10. Are willing and able to provide written informed consent.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
75
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Are pregnant or breastfeeding;
2. Currently using marijuana or other medicinal cannabis products; Use of medical
cannabis products > 6 months prior to Screening is acceptable;
3. History of cannabis use disorder (score of 8 or higher on The Cannabis Use Disorder
Identification Test - Revised (CUDIT-R);
4. Current or previous allergies or allergic responses to any of the components of the
study treatment (e.g., THC, CBD, MCT);
5. Current or previous allergies or allergic responses to any of the components of the
rescue medication (e.g. paracetamol, ibuprofen, aspirin, other NSAIDs);
6. Significant cardiac disease (e.g. poorly controlled hypertension, symptomatic
ischaemic heart disease, symptomatic heart failure);
7. Chronic liver disease with aspartate aminotransferase (AST) or alanine
aminotransferase (ALT) >3 times the upper level or normal limits;
8. Chronic renal impairment with eGFR <30mL/min;
9. Taking sildenafil or other PDE5 inhibitors;
10. Being treated with known inducers/inhibitors of CYP3A4, in particular clarithromycin,
rifampicin, azole antifungals, antiretroviral agents, anticonvulsants (phenytoin,
carbamazepine), SSRI within 30 days of study commencement; Use of such enzyme-altering
agents is prohibited throughout the study.
11. Have a major psychiatric disorder (e.g. schizophrenia, psychosis, bipolar disorder,
but not anxiety or depression), by history or examination;
12. Are currently using any illicit drug (including, but not limited to, amphetamines,
cocaine);
13. Have a history of other substance abuse disorder (as defined by DSM-5);
14. Have active substance abuse disorder (alcohol, illicit drugs);
15. Other clinically relevant abnormal findings in physical examination, clinical
chemistry, haematology, or vital signs, which in the opinion of the Investigator, may
put the participant at risk of adverse events;
16. Other chronic disease (other than chronic pain) that in the opinion of the
Investigator may impact the safety, efficacy and/or pharmacokinetics of the study
drug;
17. Are currently participating in, or have participated (in the last 30 days) in a drug
or device clinical trial;
18. Currently using opioids (including but not limited to paracetamol+codeine
combinations, codeine, tramadol, tapentadol, buprenorphine) and not willing to cease
opioids for the duration of the study;
19. COVID-19 vaccination within two (2) weeks of study assessments:
1. Study assessments should not commence until two (2) weeks after a COVID-19
vaccination dose (first, second or booster dose)
2. Subsequent COVID-19 vaccination doses (first, second or booster dose) should not
be administered until 7 days after Day 35 study assessments have been completed.
20. Back and/or neck surgery within three (3) months of Screening; or
21. Have history of metastatic cancer or are currently receiving treatment for cancer.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
N/A
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 1/Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
20/09/2021
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
21/06/2022
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
28
Query!
Recruitment in Australia
Recruitment state(s)
NSW
Query!
Recruitment hospital [1]
0
0
ACRN - Australian Clinical Research Network - Maroubra
Query!
Recruitment hospital [2]
0
0
Holdsworth House Medical Practice - Sydney
Query!
Recruitment postcode(s) [1]
0
0
2035 - Maroubra
Query!
Recruitment postcode(s) [2]
0
0
2000 - Sydney
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Cymra Life Sciences
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a non-randomised, single arm, open-label study of medical cannabis, Cybis™ 10:25, in
participants with chronic back or neck pain in which participants receive escalating doses of
Cybis™ 10:25.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT04976738
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Richard Chye
Query!
Address
0
0
Cymra Life Sciences
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT04976738
Download to PDF